Carboxypeptidase U (TAFIa) Is Rapidly Activated and Deactivated Following Thrombolysis and Thrombectomy in Stroke Patients

• Published in: Translational stroke research 2022-12, Vol.13 (6), p.959-969
• Main Authors: Mertens, Joachim C., Blanc-Guillemaud, Vanessa, Claesen, Karen, Cardona, Pere, Hendriks, Dirk, Tyl, Benoit, Molina, Carlos A.
• Format: Article
• Language: English
• Subjects: Antigens; Biomedical and Life Sciences; Biomedicine; Blood clots; Cardiology; Clinical practice guidelines; Demographics; Informed consent; Ischemia; Neurology; Neurosciences; Neurosurgery; Original Article; Patients; Sample size; Stroke; Thrombolytic drugs; Vascular Surgery; Veins & arteries
• ISSN: 1868-4483; 1868-601X
• DOI: 10.1007/s12975-021-00962-w

The antifibrinolytic enzyme carboxypeptidase U (CPU, TAFIa, CPB2) is an appealing target for the treatment of acute ischemic stroke (AIS). Increased insights in CPU activation and inactivation during thrombolysis (rtPA) with or without endovascular thrombectomy (EVT) are required to develop CPU inhibitors as profibrinolytic agents with optimal benefits/risks. Therefore, CPU kinetics during ischemic stroke treatment were evaluated. AIS patients with documented cerebral artery occlusion receiving rtPA ( N  = 20) or rtPA + EVT ( N  = 16) were included. CPU activation during thrombolysis was measured by an ultrasensitive HPLC-based CPU activity method and by an ELISA measuring both CPU and inactivated CPU (CPU + CPUi). Intravenous blood samples were collected at admission and throughout the first 24 h. Additional in situ blood samples were collected in the rtPA + EVT cohort proximal from the thrombus. The NIHSS score was determined at baseline and 24 h. CPU activity and CPU + CPUi levels increased upon rtPA administration and reached peak values at the end of thrombolysis (1 h). High inter-individual variability was observed in both groups. CPU activity decreased rapidly within 3 h, while CPU + CPUi levels were still elevated at 7 h. CPU activity or CPU + CPUi levels were similar in in situ and peripheral samples. No correlation between CPU or CPU + CPUi and NIHSS or thrombus localization was found. The CPU system was rapidly activated and deactivated following thrombolysis and thrombectomy in stroke patients, suggesting that a CPU inhibitor would have to be administered during rtPA infusion and over the next few hours. The high CPU generation variability suggests that some patients may not respond to the treatment. EudraCT number 2017-002760-41.